In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InterMune, Inc.

http://www.intermune.com

Latest From InterMune, Inc.

Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes

Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.

Companies Clinical Trials

BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation

Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.

Approvals Business Strategies

Neuroplast Develops Safer Stem Cell Therapy For Spinal Injuries

Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.

Emerging Company Profile Neurology

Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually

When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?

Stock Watch Companies
See All

Company Information

UsernamePublicRestriction

Register